Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Kumamoto University |
---|---|
Information provided by: | Kumamoto University |
ClinicalTrials.gov Identifier: | NCT00110448 |
The purpose of this study is to determine the effects of low-dose aspirin for the primary prevention of vascular events in patients with type 2 diabetes in Japan.
Condition | Intervention | Phase |
---|---|---|
Coronary Disease Arteriosclerosis Diabetes Mellitus, Type 2 |
Drug: Aspirin Drug: No aspirin |
Phase IV |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Double Blind (Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial |
Enrollment: | 2539 |
Study Start Date: | December 2002 |
Study Completion Date: | July 2008 |
Primary Completion Date: | May 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Active Comparator
Aspirin use
|
Drug: Aspirin
Aspirin 81 mg or 100 mg per day
|
2: Active Comparator
No aspirin use
|
Drug: No aspirin
No aspirin use
|
There is a worldwide epidemic of diabetes and the number of individuals with diabetes is set to increase further. As individuals with diabetes are at high risk of accelerated atherosclerosis and thrombotic vascular events, the significant proportion of the cardiovascular disease burden is projected to be among this population. JPAD is a multicenter study with a prospective randomized open, blinded end-point (PROBE) design. The doses administered are aspirin 81 mg/day or 100 mg/day, the latter being enteric-coated Aspirin.
The primary objective was to compare the effect of aspirin on atherosclerotic events including cardiovascular events, cerebral vascular event, and other vascular events.
We also analyze hemorrhagic events in this RCT.
Ages Eligible for Study: | 30 Years to 85 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Japan | |
Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University | |
Kumamoto, Japan, 860-8556 | |
Japan, Nara | |
First Department of Internal Medicine, Nara Medical University | |
Kashihara, Nara, Japan, 634-8522 |
Principal Investigator: | Hisao Ogawa, MD | Professor of Medicine, Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University |
Principal Investigator: | Yoshihiko Saito, MD | Professor of Medicine, First Department of Internal Medicine, Nara Medical University |
Responsible Party: | Kumamoto University ( Hisao Ogawa ) |
Study ID Numbers: | H14-Kouka(Seikatsu)-025 |
Study First Received: | May 9, 2005 |
Last Updated: | September 22, 2008 |
ClinicalTrials.gov Identifier: | NCT00110448 |
Health Authority: | Japan: Ministry of Health, Labor and Welfare |
type 2 diabetes coronary heart diseases primary prevention atherosclerosis aspirin |
Atherosclerosis Arterial Occlusive Diseases Heart Diseases Metabolic Diseases Myocardial Ischemia Diabetes Mellitus Vascular Diseases Endocrine System Diseases Arteriosclerosis |
Ischemia Coronary Disease Aspirin Diabetes Mellitus, Type 2 Endocrinopathy Metabolic disorder Glucose Metabolism Disorders Coronary Artery Disease |
Anti-Inflammatory Agents Molecular Mechanisms of Pharmacological Action Cyclooxygenase Inhibitors Hematologic Agents Physiological Effects of Drugs Enzyme Inhibitors Fibrinolytic Agents Cardiovascular Agents Pharmacologic Actions Fibrin Modulating Agents |
Analgesics, Non-Narcotic Sensory System Agents Therapeutic Uses Platelet Aggregation Inhibitors Cardiovascular Diseases Anti-Inflammatory Agents, Non-Steroidal Analgesics Peripheral Nervous System Agents Antirheumatic Agents Central Nervous System Agents |